News Granules India Limited

Stocks

GRANULES

INE101D01020

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 11:00:52 10/07/2026 BST			5-day change	1st Jan Change
889.55 ^INR	+0.95%		+6.77%	+48.62%

07-06	Granules India Gets Sole First-to-File Status for Sodium Oxybate Extended-Release for Oral Suspension	MT
06-12	Sushil Finance Starts Granules India at Buy with INR963 Price Target	MT

All News

Mentions Relevance

07-06	Granules India Gets Sole First-to-File Status for Sodium Oxybate Extended-Release for Oral Suspension	MT
06-12	Sushil Finance Starts Granules India at Buy with INR963 Price Target	MT
05-01	Choice Equity Broking Downgrades Granules India to Add from Buy; Price Target is INR835	MT
04-29	Granules India Limited, Q4 2026 Earnings Call, Apr 29, 2026
04-29	Granules India : Q4FY26 Revenue from operations at INR 14,706 Mn up 23% YoY, EBITDA at INR 3,521 Mn up 40% YoY, PBT before Exceptional Item at INR 2,464 Mn up 48% YoY, PAT at INR 2,016 Mn up 33% YoY.	PU
04-29	Granules India Q4 consol profit 2.02 billion rupees	RE
04-29	Granules India Limited Recommends Final Dividend for the Financial Year 2025-2026	CI
04-29	Granules India's fourth-quarter profit jumps on strong demand	RE
04-29	Granules India Limited Designates Mr. Harsha Chigurupati as Senior Management Personnel, Effective April 30, 2026	CI
04-29	Granules India Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026	CI
04-09	Indian drugmaker Granules to tighten oversight after US FDA warning, exec says	RE
03-31	Granules receives VAI classification after US FDA inspection	RE
03-05	Granules India : Packaging Facility in US gets FDA EIR with No Action Indicated Status	PU
03-05	Granules India Arm Gets "No Action Indicated" Status from US FDA for Viginia Unit; Shares Up 3%	MT
03-05	Granules says packaging facility in US gets FDA EIR with No Action Indicated status	RE
02-24	Granules India: Analysts Bet on Continued Upside
02-22	Granules India Limited announced that it has received INR 6.656249925 billion in funding	CI
01-28	Granules India : SERP Join Handsto Strengthen Breast Cancer Screening in Sangareddy	PU
01-23	Granules India Limited, Q3 2026 Earnings Call, Jan 23, 2026
01-23	Granules India quarterly profit jumps on strong demand in North America, Europe	RE
01-23	Granules Dec-quarter Consol Profit 1.50 Billion Rupees	RE
01-22	Granules India : Q3FY26 Revenue from operations at INR 13,879 Mn up 22% YoY, EBITDA at INR 3,081 Mn up 34% YoY, PBT at INR 2,022 Mn up 32% YoY, PAT at INR 1,502 Mn up 28% YoY.	PU
01-22	Granules India Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025	CI
01-08	Granules India : Pharmaceuticals, Inc. Receives FDA Tentative Approval with 180-Day Exclusivity for Generic Amphetamine Extended-Release Tablets (gDYANAVEL XR)	PU
01-08	Granules India Arm Gets US FDA's Tentative Nod for Amphetamine Extended-Release Tablets	MT